Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome

@article{Bruyre2014OsteoporosisIP,
  title={Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome},
  author={Olivier Bruy{\`e}re and Jean-Yves Reginster},
  journal={Endocrine},
  year={2014},
  volume={48},
  pages={65-68}
}
Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses… Expand
ROLE OF BONE DENSITOMETRY IN PATIENTS TAKING SELECTIVE SEROTONINE REUPTAKE INHIBITORS : AN OBSERVATIONAL STUDY
Purpose of the study were to evaluate the effect of selective serotonine reuptake inhibitor therapy on bone density in patients affected by panic disorder and and to detect a correlation withExpand
Do Selective Serotonin Reuptake Inhibitors (SSRIs) Cause Fractures?
TLDR
A strong, consistent, and temporal relationship between SSRIs and fractures is found, which appears to follow a biological gradient, however, specificity and biological plausibility remain concerns. Expand
Drug-induced bone loss: a major safety concern in Europe
TLDR
This article will review the common drugs identified as the causes of bone loss and the risk factors and management in European countries and determine the best prevention and treatment strategies. Expand
Nutrition status, bone mass density, and selective serotonin reuptake inhibitors.
TLDR
A sub-analysis within SSRI users was conducted to calculate the odds ratio (OR) of having a low BMD t-score given SSRI exposure and inadequate daily micronutrient intake, and whether there are potential interactions between micronsutrients and SSRI use on BMD. Expand
Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors
ABSTRACT Many commonly prescribed medications, such as selective serotonin reuptake inhibitors, proton pump inhibitors, thiazolidinediones, aromatase inhibitors, and androgen deprivation therapy,Expand
Normal Bone Microstructure and Density But Worse Physical Function in Older Women Treated with Selective Serotonin Reuptake Inhibitors, a Cross-Sectional Population-Based Study
TLDR
Treatment with SSRIs was, independently of covariates, associated with worse physical function without any signs of inferior bone geometry and microstructure in older women. Expand
Evaluation of antidepressant effects of zoledronate in rats
TLDR
Zoledronate (0.45 mg/kg) has shown significant reduction in duration of immobility in both forced swim test and tail suspension test, and the positive effects of bisphosphonates, including improvement in anxiety or depression, is an area of research in the recent years. Expand
High Serum Serotonin Predicts Increased Risk for Hip Fracture and Nonvertebral Osteoporotic Fractures: The MrOS Sweden Study
TLDR
Novel data is presented showing that high levels of serotonin predict an increased risk for hip fracture and nonvertebral osteoporotic fractures, as well as on bone mineral density (BMD) and muscle strength, in humans. Expand
Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients
TLDR
Overall, there is high tolerability for early SSRI treatment, whereas the occurrence of somnolence leads to discontinuation, while patients suffering from cardiovascular risk factors or osteoporosis tended to adhere to the therapy. Expand
Differential effects of serotonin reuptake inhibitors fluoxetine and escitalopram on bone markers and microarchitecture in Wistar rats
TLDR
The study shows that fluoxetine reduces bone formation possibly through reduced pCREB mediated by the action of gut serotonin in osteoblasts and that escitalopram can be a better treatment option as far as adverse effects on bone are concerned. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 45 REFERENCES
Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression
TLDR
Observations are consistent with a role for the serotonergic system in regulating bone metabolism, as well as with a first-line treatment for depression, among SSRIs users. Expand
Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?
TLDR
With mounting evidence for an effect on bone, this review considers the question of causality and whether selective serotonin reuptake inhibitors should be considered among those medications that contribute to bone loss, and therefore prompt clinicians to evaluate BMD proactively. Expand
Antidepressant medications and osteoporosis.
TLDR
The body of evidence suggests that SSRIs should be considered in the list of medications that are risk factors for osteoporotic fractures, and identifies themes for future research. Expand
SSRIs, bone mineral density, and risk of fractures — a review
TLDR
It is concluded that it is not possible to determine whether SSRIs may negatively influence bone regulation or are innocent bystanders, and it is likely that only a large, prospective, long-term study designed to investigate changes in BMD will be able to answer the question. Expand
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures.
TLDR
Use of SSRIs but not TCAs is associated with an increased rate of bone loss at the hip in this cohort of older women. Expand
Risk of Fractures with Selective Serotonin-Reuptake Inhibitors or Tricyclic Antidepressants
TLDR
Most studies compared SSRIs with tricyclic antidepressants (TCAs) and found similar or greater risk of fracture associated with use of an SSRI, but there may be a possible correlation with SSRI or TCA use and risk of fractures. Expand
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.
TLDR
BMD was lower among those reporting current SSRI use, but not among users of other antidepressants, similar to that seen with glucocorticoids. Expand
Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS)
TLDR
An increased risk of fractures in individuals who used SSRI or SNRI is found, even after controlling for multiple risk factors, in adults aged 50 + . Expand
Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose
TLDR
Increasing age was associated with more fractures in users of selective serotonin reuptake inhibitors and tricyclic antidepressants, whereas for anxiolytics and sedatives, more fractures were seen among the younger users, and a hospital diagnosis of depression or manic depression was not a risk factor for fractures. Expand
Use of selective serotonin reuptake inhibitors and risk of fracture: A systematic review and meta‐analysis
TLDR
A meta‐analysis of 12 observational studies showed that the overall risk of fracture was higher among people using SSRIs and the strength of the association decreased with a longer window of SSRI administration before the index date. Expand
...
1
2
3
4
5
...